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Antidepressant-like effects of 5-hydroxytryptamine subtype 3 (5-HT3) antagonists including tropisetron
and ondansetron have been previously demonstrated in the literature. It was reported that stimulation of
5-HT3 receptors activate the nitric oxide-cyclic guanosine monophosphate (NO-cGMP) pathway, which is
involved in regulation of behavioral and emotional functions. In our study, treating animals with tro-
pisetron (5, 10, and 30 mg/kg) and ondansetron (0.01 and 0.1 mg/kg) signiﬁcantly decreased the im-
mobility time in forced swimming test (FST) and tail-suspension test (TST). Co-administration of sub-
effective doses of tropisetron (1 mg/kg) and ondansetron (0.001 mg/kg) with subeffective dose of L-NAME
(10 mg/kg, nonselective NO synthase (NOS) inhibitor) and 7-nitroindazole (25 mg/kg, neural NOS in-
hibitor) exerted antidepressant-like effect in FST and TST, while aminoguanidine (50 mg/kg, inducible
NOS inhibitor) did not enhance the antidepressant-like effect of 5-HT3 antagonists. Besides, L-arginine
(750 mg/kg, NO precursor) and sildenaﬁl (5 mg/kg, phosphodiesterase inhibitor) suppressed the anti-
immobility effect of 5-HT3 antagonists. None of the treatments altered the locomotor behavior of mice in
open-ﬁeld test. Also, hippocampal (but not cortical) nitrite level was signiﬁcantly lower in tropisetron
and ondansetron-treated mice compared with saline-injected mice. Also, co-administration of 7-ni-
troindazole with tropisetron or ondansetron caused a signiﬁcant decrease in hippocampal nitrite levels.
In conclusion, we suggest that antidepressant-like effect of tropisetron and ondansetron are partially
mediated by modulation of NO-cGMP pathway.
& 2016 Published by Elsevier B.V.1. Introduction
Depression, one of the most common psychiatric disorders, has
become a public health concern (Silva et al., 2014). In view of the
fact that the prevalence of depression is progressively high
(Compton et al., 2006), increasing attention is paid to treatment of
patients with depression. Amongst the several routine prescribedtric oxide; NOS, nitric oxide
S, neuronal nitric oxide syn-
rced swimming test; TST, tail
eal; NIH, National Institutes
7-nitroindazole; L-arg, L-ar-
ariance; PFC, prefrontal
rch Center, Tehran University
.
ur@yahoo.com (A. Dehpour).
dered as the ﬁrst author.antidepressant medications, which are mainly based on mono-
amine regulation, few are highly expected to show the desired
outcomes (Arroll et al., 2005; Berton and Nestler, 2006). Thus,
ﬁnding new antidepressants with favorable pharmacological
properties is advantageous.
5-hydroxytryptamine 3 (5-HT3) receptors are the only ligand-
gated ion channel subtype among the 5-HT receptor family (Hoyer
and Schoeffter, 1991). Tropisetron and ondansetron are highly se-
lective competitive inhibitors of 5-HT3 receptors (Broocks, 1992).
These receptors are widely distributed in the central nervous
system and play a pivotal role in regulation of a variety of pro-
cesses in different brain structures including hippocampus. Evi-
dence indicates that tropisetron and ondansetron exert anti-
depressant-like properties in rodent behavioral tests such as
forced swimming test (FST), tail suspension test (TST), and learned
helplessness (Bravo and Maswood, 2006; Martin et al., 1992; Na-
kagawa et al., 1998; Ramamoorthy et al., 2008). Also, several
clinical investigations have assessed the beneﬁcial effects of
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anxiety and depression (Haus, 2000; Hewlett et al., 2003; Le-
crubier et al., 1993). These 5-HT3 antagonists have desirable
pharmacological proﬁle and cause few adverse effects, and are
consequently well-tolerated in patients (Greenshaw and Silver-
stone, 1997; Rajkumar and Mahesh, 2010).
It has been reported that nitric oxide (NO) is involved in many
physiological functions of the 5-HT3 receptors. In this context,
activation of 5-HT3 receptors has been reported to stimulate nitric
oxide synthase (NOS) as well as cyclic guanosine monophosphate
(cGMP) pathways (Giordano and Schultea, 2004; Wetzel et al.,
1998). The NO–cGMP pathway is known to be implicated in reg-
ulation of various (patho)physiologic behavioral and emotional
functions (Denninger and Marletta, 1999), and has been suggested
as a therapeutic target for depression (Harkin et al., 1999). In this
regard, many studies demonstrated that NOS and cGMP inhibition
produce antidepressant-like effects in FST and TST (Heiberg et al.,
2002; Zomkowski et al., 2010).
Although the antidepressant-like effect of tropisetron and on-
dansetron in the FST and TST has been reported in rodents, un-
derlying mechanisms through which these drugs exert these an-
tidepressant-like effects are not well deﬁned. In this study, we
investigated the possible participation of NO–cGMP pathway in
the antidepressant effect of ondansetron and tropisetron in mice.2. Materials and methods
2.1. Animals
The animals used for this study consisted of male NMRI mice
(20–30 g) brought from the Pasteur Institute, Tehran, Iran. All an-
imals were housed in groups of four or ﬁve, and were kept at the
temperature of 21–23 °C under 12 h regular light/dark cycle. Mice
were given access to food and water ad lib. All experiments were
carried out between 10:00 and 14:00. All procedures were per-
formed in accordance with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals (NIH Publica-
tions No. 80-23, revised 1978) and the institutional guidelines for
animal care and use (Department of Pharmacology, School of
Medicine, TUMS, No. 91-01-159-18022) (ethical permit number:
3186). All experimental groups included 6–8 animals and full ef-
forts were made to minimize the use of animals and to optimize
their comfort (number of animals in each experimental group
were shown in Fig. captions).
2.2. Drugs
The following drugs were used in this study: tropisetron, on-
dansetron, ﬂuoxetine, NG-L-arginine methyl ester (L-NAME), ami-
noguanidine, 7-Nitroindazole (7-NI), L-arginine (L-arg), and silde-
naﬁl (All were purchased from Sigma, St Louis, MO, USA). Except
7-NI which was dissolved in Tween80 1% solution, all drugs were
freshly dissolved in physiological saline and were prepared im-
mediately before the experiments. All drugs were injected through
intraperitoneal (i.p.) route and with a volume of 5 ml/kg body
weight (Turner et al., 2011).
2.3. Open ﬁeld test (OFT)
The OFT was used to evaluate the locomotor behavior of ani-
mals (Haj-Mirzaian et al., 2015a; Kulesskaya and Voikar, 2014). The
open-ﬁeld apparatus was made of white opaque Plexiglas
(50 cm50 cm30 cm) which was dimly illuminated. Each
mouse was placed gently on the center square (30 cm30 cm),
and behaviors were recorded by a camera for 5 min and wereanalyzed by Ethovision software version 8 (Noldus, Netherlands).
The total distance moved (horizontal activity) in the OFT was
evaluated to ensure that the decrease or increase in animal's
motionlessness in FST/TST is not due to the alterations in loco-
motor activity.
2.4. Forced swimming test (FST)
For conducting the FST, the animals were placed in an open
cylinder-shaped ﬂask (diameter 10 cm, height 25 cm) ﬁlled with
19 cm water at 2471 °C. The FST was used to assess behavioral
immobility of mice as a selective standard animal test for anti-
depressant treatment (Haj-Mirzaian et al., 2015b; Porsolt et al.,
1977). Being allowed to swim for 6 min, each mouse was assumed
immobile when stopped struggling and ﬂoated motionless in the
water, making only the movements for keeping its head above
water. The time of remaining immobile within the last 4 min of the
test was recorded.
2.5. Tail suspension test (TST)
In brief, each mouse was suspended on the edge of a rod 50 cm
above a table top using adhesive Scotch tape, placed approxi-
mately 1 cm from the tip of the tail. Tail climbing was prevented
by passing the mouse's tail through a small plastic cylinder prior to
suspension. The duration of immobility was manually measured
for a 6 min observation period. Mice were considered immobile
only when they hung down passively and were completely mo-
tionless (Cryan et al., 2005; Steru et al., 1985). Compounds that
decrease immobility and increase active behaviors in FST and TST
are considered to suppress indices of depression.
2.6. Treatments
First, we studied the effects of tropisetron and ondansetron on
the FST, TST, and OFT. Intraperitoneal injection of ondansetron
(0.001, 0.005, 0.01, and 0.1 mg/kg) and tropisetron (1, 5, 10, and
30 mg/kg) 30 min before the behavioral tests was performed to
evaluate the effective and subeffective doses of these drugs. These
doses and times of administration were based upon our pilot
studies and previous reports (Bravo and Maswood, 2006; Rama-
moorthy et al., 2008). Fluoxetine (20 mg/kg), a selective serotonin
reuptake inhibitor, was used as a standard antidepressant drug.
Fluoxetine was administered intraperitoneally 30 min before the
tests and the results were considered as the positive control group
(Haj-Mirzaian et al., 2014; Kordjazy et al., 2015; Moretti et al.,
2012). Also, in order to exclude the effect of saline administration
on behavioral tests, saline (5 ml/kg) was injected 30 min before
the tests into control group.
In the same way, we assessed the effects of L-NAME (a non-
selective NOS inhibitor, 10 mg/kg, 45 min prior to behavioral tests),
aminoguanidine (a selective inducible NOS or iNOS inhibitor,
50 mg/kg, 45 min prior to behavioral tests), 7-NI (a selective
neuronal NOS or nNOS inhibitor, 25 mg/kg, 30 min prior to beha-
vioral tests), L-arg (an NO precursor, 750 mg/kg, 45 min prior to
behavioral tests), and sildenaﬁl (a selective phosphodiesterase
(PDE)-5 inhibitor) (5 mg/kg, 30 min prior to behavioral tests) on
behaviors of mice in the FST, TST, and OFT. The doses were based
on a pilot study and also previous studies (Amiri et al., 2015a; da
Silva et al., 2000; Ghasemi et al., 2008; Harkin et al., 2004;
Kordjazy et al., 2015; Sadaghiani et al., 2011). To exclude the effect
of vehicle administration on behavioral assessments, saline or
Tween80 1% (5 ml/kg) were injected 30/45 min before the tests
into control groups.
Further, the probable involvement of nitrergic system on the
antidepressant-like activity of these 5-HT3 antagonists was
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doses of L-NAME (10 mg/kg), aminoguanidine (50 mg/kg), and
7-NI (25 mg/kg) along with the subeffective doses of tropisetron
and ondansetron. Also, the effective doses of tropisetron and on-
dansetron along with subeffective L-arg (750 mg/kg) and sildenaﬁl
(5 mg/kg) were co-administered to the animals. After the treat-
ments, animals were subjected to the OFT, and afterwards, to ei-
ther FST or TST. To exclude the effect of vehicle administration on
behavioral assessments, saline or Tween80 1% (5 ml/kg) were in-
jected along with tropisetron and ondansetron into control groups.
2.7. Nitrite assay
To determine the NO level in hippocampus and prefrontal
cortex (PFC), we measured the nitrite level as the stable NO end
product in another group of animals after injection of different
doses of tropisetron and ondansetron in the presence and absence
of selective NOS inhibitor (Granger et al., 1996; Kordjazy et al.,
2015). Each animal was decapitated 30 min after drug injection
under halothane (2%) anesthesia and the hippocampus and PFC
were dissected on ice-cold surface and immediately immersed
into liquid nitrogen. Tissue homogenates were prepared and ni-
trite levels were determined by a colorimetric assay based on the
Griess reaction. First, 100 μL of each sample was mixed with
100 μL Griess reagent (each hippocampus/PFC of experimental
mice was lysed separately). Following 10 min incubation in 20 °C,
the absorbance was quantiﬁed at 540 nm in an automated plate
reader. Concentration of nitrite was determined by reference to a
standard curve plotted for sodium nitrite (Sigma, USA) and nor-
malized to the weight of each sample.
2.8. Statistical analysis
Statistical analyses and interpretations were performed using
the SPSS and graph-pad Prism software package. The one-way and
two-way analyses of variance (ANOVAs), followed by tukey's
multiple comparison test,were used for comparing the immobility
times, locomotor activities, and hippocampal nitrite levels be-
tween the experimental groups. The analysis method used in each
part of the study is mentioned in the Section 3 and “Fig. captions”.
Finally, Po0.05 was considered signiﬁcant.Fig. 1. Antidepressant effect of tropisetron: Effect of acute administration of tro-
pisetron (1, 5, 10, and 30 mg/kg, i.p., 30 min before the tests): (A) Duration of im-
mobility in FST (n¼8). (B) Duration of immobility in TST (n¼6–8). (C) Distance
moved in OFT (n¼8). Values are expressed as the mean7S.E.M, and were analyzed
using one-way ANOVA followed by tukey’s post hoc test.'*Po0.05, **Po0.01, and
***Po0.001 compared with saline-treated (S) group. Fluoxetine (20 mg/kg, i.p.,
30 min before the tests) (FLX) was used as the positive control group.3. Results
3.1. Effect of 5-HT3 antagonists on the immobility time in the FST,
TST, and on the locomotor activity in the OFT
One-way ANOVA analysis showed signiﬁcant effect of tropise-
tron treatment on the FST (F (5, 42)¼6.891, Po0.001, Fig. 1A) and
TST (F (5, 36)¼6.290, Po0.001, Fig. 1B); however, no signiﬁcant
effect was observed in the OFT (F (5, 42)¼0.2830, P40.05, Fig. 1C).
Tukey's post hoc analysis showed that treating mice with tropi-
setron (5, 10, and 30 mg/kg) signiﬁcantly decreased the immobility
time both in the FST (Po0.05, Po0.01, and Po0.001 respectively,
Fig. 1A) and TST (Po0.05, Po0.01, and Po0.01 respectively,
Fig. 1B) when compared with the saline-treated animals. However,
tropisetron (1 mg/kg) did not show antidepressant-like effect in
these tests (P40.05). Also, tropisetron did not produce signiﬁcant
changes in the distance moved by mice in the OFT, as compared
with saline-injected control group (P40.05, Fig. 1C).
As shown in Fig. 2, one-way ANOVA analysis revealed that
ondansetron treatment signiﬁcantly affects animals' behavior in
the FST (F (5, 42)¼4.752, Po0.01, Fig. 2A) and TST (F (5, 34)¼
4.719, Po0.01, Fig. 2B), but not in the OFT (F (5, 42)¼0.1843,
P40.05, Fig. 2C). Multiple comparisons using tukey's post hocanalysis demonstrated that although ondansetron (0.001 mg/kg)
did not produce anti-immobility effect (P40.05, Fig. 2A), at doses
0.005, 0.01, and 0.1 mg/kg signiﬁcantly decreased the immobility
time in the FST when compared to saline-injected group (Po0.05,
Fig. 2. Antidepressant effect of ondansetron: Effect of acute administration of on-
dansetron (0.001, 0.005, 0.01, and 0.1 mg/kg, i.p., 30 min before the tests):
(A) Duration of immobility in FST (n¼8). (B) Duration of immobility in TST (n¼6–
7). (C) Distance moved in OFT (n¼8). Values are expressed as the mean7S.E.M,
and were analyzed using one-way ANOVA followed by tukey's post hoc test.
*Po0.05 and **Po0.01 compared with the saline-treated (S) group. Fluoxetine
(20 mg/kg, i.p., 30 min before the tests) (FLX) was used as the positive control
group.
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tration of ondansetron (0.01 and 0.1 mg/kg) induced an anti-im-
mobility effect when compared with saline-injected group(Po0.05 and Po0.01 respectively, Fig. 2B). However, lower doses
of this drug (0.005 and 0.001 mg/kg) did not alter the duration of
immobility in the TST (P40.05, Fig. 2B). None of the applied doses
of ondansetron affected the total distance moved in the OFT
(P40.05, Fig. 2C). On the other hand, our data show that the anti-
immobility effect of tropisetron/ondansetron was similar to the
ﬂuoxetine's, which signiﬁcantly reduced the immobility time in
both FST and TST, but did not alter the locomotor activity of ani-
mals in the OFT.
3.2. Effect of NOS inhibitors on the effect of subeffective doses of
5-HT3 antagonists in the FST and TST and on the distance moved in
OFT
Figs. 3 and 4 show the effects of subeffective doses of NOS in-
hibitors on the behavioral tests including FST, TST, and OFT. Tu-
key's analysis showed that administration of L-NAME (10 mg/kg)
as a non-speciﬁc NOS inhibitor, 7-NI (25 mg/kg) as a selective
nNOS inhibitor, and aminoguanidine (50 mg/kg) as a selective
iNOS inhibitor had no effect on the behavioral tests in mice when
compared with saline/Tween80-treated groups (P40.05).
On the next step, the effects of co-administration of sub-
effective doses of 5-HT3 antagonists with subeffective doses of
NOS inhibitors on behavioral tests were determined. Tukey's post
hoc analysis demonstrated that co-treatment of mice with tropi-
setron (1 mg/kg) and L-NAME (10 mg/kg) produced anti-
depressant-like effect in FST (Po0.01, Fig. 3A) and TST (Po0.05,
Fig. 3B) when compared with saline-treated group. Two-way
ANOVA showed signiﬁcant or non-signiﬁcant effect for tropisetron
treatment (F (1, 28)¼6.781, Po0.05) and (F (1, 20)¼8.586,
Po0.01), L-NAME treatment (F (1, 28)¼6.945, Po0.05) and (F (1,
20)¼0.8823, P40.05), and L-NAME tropisetron interaction (F (1,
28)¼3.263, P40.05) and (F (1, 20)¼0.0024, P40.05) in FST and
TST, respectively.
Using tukey's multiple comparison, 7-NI (25 mg/kg) and tro-
pisetron (1 mg/kg) co-administration exerted signiﬁcant anti-im-
mobility effect in FST (Po0.01, Fig. 3D) and TST (Po0.001, Fig. 3E)
when compared with Tween80-treated group. Two-way ANOVA
showed signiﬁcant or non-signiﬁcant effect for tropisetron treat-
ment (F (1, 27)¼10.46, Po0.01) (F (1, 22)¼19.69, Po0.001), 7-NI
treatment (F (1, 27)¼5.873, Po0.05) (F (1, 22)¼4.564, Po0.05),
and their interaction (F (1, 27)¼4.953, Po0.05) (F (1, 22)¼1.27,
P40.05) in FST and TST, respectively.
However, aminoguanidine (50 mg/kg) did not potentiate the
effect of subeffective dose of tropisetron in both FST (P40.05,
Fig. 3G) and TST (P40.05, Fig. 3H). Likewise, no signiﬁcant effect
was observed in two-way ANOVA analysis for tropisetron treat-
ment (F (1, 28)¼1.282, P40.05) (F (1, 22)¼3.980, P40.05), ami-
noguanidine treatment (F (1, 28)¼0.2302, P40.05) (F (1, 22)¼
0.0015, P40.05), and their interaction (F (1, 28)¼0.2358, P40.05)
(F (1, 22)¼0.0055, P40.05) in FST and TST, respectively.
Also, two-way ANOVA analysis followed by tukey's post hoc
test showed that none of these treatments affected the locomotor
activity of mice in the OFT (P40.05, Fig. 3C, F, and I).
Fig. 4 shows that co-administration of the subeffective dose of
L-NAME (10 mg/kg) with ondansetron (0.001 mg/kg) induced a
signiﬁcant antidepressant-like effect in the mouse FST (Po0.05,
Fig. 4A) and TST (Po0.05, Fig. 4B), in comparison with saline-
treated mice when analyzed by tukey's post hoc test. In two-way
ANOVA we also detected signiﬁcant or non-signiﬁcant effect for
ondansetron treatment (F (1, 28)¼4.804, Po0.05) (F (1, 23)¼
8.183, Po0.01), L-NAME treatment (F (1, 28)¼4.982, Po0.05) (F (1,
23)¼1.498, P40.05), and their interaction (F (1, 28)¼1.360,
P40.05) (F (1, 23)¼0.1512, P40.05) in FST and TST, respectively.
The subeffective dose of 7-NI (25 mg/kg) administered in
combination with subeffective ondansetron (0.001 mg/kg)
Fig. 3. Role of NO in the antidepressant effect of tropisetron: Effect of L-NAME (10 mg/kg) and tropisetron (1 mg/kg) co-administration on the (A) FST (n¼8), (B) TST (n¼6–
7), and (C) OFT (n¼8). Effect of 7-nitroindazole (7-NI, 25 mg/kg) and tropisetron (1 mg/kg) co-administration on the (D) FST (n¼7–8), (E) TST (n¼6–7), and (F) OFT (n¼8).
Effect of aminoguanidine (AG, 50 mg/kg) and tropisetron (1 mg/kg) co-administration on the (G) FST (n¼8), (H) TST (n¼6–7), and (I) OFT (n¼8). Values are expressed as the
mean7S.E.M, and were analyzed using two-way ANOVA followed by tukey's post hoc test. *Po0.05, **Po0.01, ##Po0.01, and ###Po0.001 compared with vehicle-
treated group (saline or Tween80 1%).
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(Po0.001, Fig. 4D) and TST (Po0.01, Fig. 4E) compared with
Tween80-administered group using Tukey's post hoc test. Two-
way ANOVA revealed signiﬁcant or non-signiﬁcant effect for on-
dansetron treatment (F (1, 28)¼13.04, Po0.01) (F (1, 22)¼15.15,
Po0.01), 7-NI treatment (F (1, 28)¼6.428, Po0.05) (F (1, 22)¼
4.091, p¼0.05), and their interaction (F (1, 28)¼5.591, Po0.05) (F
(1, 22)¼1.401, P40.05) in FST and TST, respectively.
Tukey's analysis revealed that concurrent administration of
subeffective doses of aminoguanidine with ondansetron did not
signiﬁcantly alter the immobility duration in FST (P40.05, Fig. 4G)
and TST (P40.05, Fig. 4H). Further analysis with two-way ANOVA
excluded any signiﬁcant effect for ondansetron treatment (F (1,
28)¼1.243, P40.05) (F (1, 22)¼6.067, Po0.05), aminoguanidine
treatment (F (1, 28)¼0.2077, P40.05) (F (1, 22)¼0.069, P40.05),
and their interaction (F (1, 28)¼0.0159, P40.05) (F (1, 22)¼0.051,
P40.05) in FST and TST, respectively.Likewise the last section, two-way ANOVA analysis followed by
multiple comparison tests showed that administration of none of
the applied drugs caused ambulation in locomotion of mice
(P40.05, Fig. 4C, F, I).3.3. Effect of L-arginine pre-treatment on the anti-immobility effect
of 5-HT3 antagonists in the FST and TST and on the distance moved in
OFT
Although L-arg (750 mg/kg) individually did not alter the im-
mobility time of mice, tukey's analysis showed that it signiﬁcantly
reversed the antidepressant-like effect of tropisetron (10 mg/kg) in
FST (Po0.01, Fig. 5A) and TST (Po0.05, Fig. 5B). Two-way ANOVA
showed signiﬁcant or non-signiﬁcant effect for tropisetron treat-
ment (F (1, 28)¼13.99, Po0.001) (F (1, 24)¼15.94, Po0.001),
L-arg treatment (F (1, 28)¼6.238, Po0.05) (F (1, 24)¼3.680,
Fig. 4. Role of NO in the antidepressant effect of ondansetron: Effect of L-NAME (10 mg/kg) and ondansetron (0.001 mg/kg) co-administration on the (A) FST (n¼8), (B) TST
(n¼6–8), and (C) OFT (n¼8). Effect of 7-nitroindazole (7-NI, 25 mg/kg) and ondansetron (0.001 mg/kg) co-administration on the (D) FST (n¼7–8), (E) TST (n¼6–7), and
(F) OFT (n¼8). Effect of aminoguanidine (AG, 50 mg/kg) and ondansetron (0.001 mg/kg) co-administration on the (G) FST (n¼8), (H) TST (n¼6–7), and (I) OFT (n¼8). Values
are expressed as the mean7S.E.M, and were analyzed using two-way ANOVA followed by tukey's post hoc test. *Po0.05, ##Po0.01, and ###Po0.001 compared with
vehicle-treated group (saline or Tween80 1%).
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24)¼4.001, p¼0.05) in FST and TST, respectively.
Our results show that pre-treatment with L-arg prevented
the antidepressant-like effect of ondansetron (0.01 mg/kg) in
the FST (Po0.01, Fig. 5D) and also the TST (Po0.01, Fig. 5E).
Also, in two-way ANOVA we found a signiﬁcant effect for on-
dansetron treatment (F (1, 28)¼12.17, Po0.01) (F (1, 22)¼
16.16, Po0.001), L-arg treatment (F (1, 28)¼7.052, Po0.05) (F
(1, 22)¼5.836, Po0.05), and their interaction (F (1, 28)¼7.052,
Po0.05) (F (1, 22)¼6.265, Po0.05) in FST and TST,
respectively.
Administration of L-arg alone or in combination with tropise-
tron/ondansetron did not affect the ambulatory behavior in the
OFT when evaluated by two-way analysis followed by tukey's test
(P40.05, Fig. 5C and F).3.4. Effect of sildenaﬁl pre-treatment on the anti-immobility effect of
5-HT3 antagonists in the FST and TST and on the distance moved in OFT
Fig. 6 shows that administration of sildenaﬁl (5 mg/kg) did not
alter the immobility time of mice individually in the FST and TST
compared with saline-treated group (P40.05). However, tukey's
analysis showed that sildenaﬁl signiﬁcantly reversed the anti-im-
mobility effect of tropisetron (10 mg/kg) in the FST (Po0.001,
Fig. 6A) and TST (Po0.05, Fig. 6B). Two-way ANOVA showed sig-
niﬁcant or non-signiﬁcant effect for tropisetron treatment (F (1,
28)¼9.949, Po0.01) (F (1, 23)¼26.04, Po0.001), sildenaﬁl
treatment (F (1, 28)¼7.883, Po0.01) (F (1, 23)¼3.642, P40.05),
and their interaction (F (1, 28)¼12.87, Po0.01) (F (1, 23)¼7.627,
Po0.05) in FST and TST, respectively.
Tukey's analysis revealed that administration of sildenaﬁl
also attenuated the antidepressant-like effect of ondansetron
Fig. 5. Effect of NO precursor on the antidepressant effect of 5-HT3 antagonists: Effect of subeffective dose of L-arginine (750 mg/kg) on the effects of tropisetron (10 mg/kg)
in (A) FST (n¼8), (B) TST (n¼6-8), and (C) OFT (n¼8). Effect of subeffective dose of L-arginine (750 mg/kg) on the effects of ondansetron (0.01 mg/kg) in (D) FST (n¼8),
(E) TST (n¼6–7), and (F) OFT (n¼8). Values are expressed as the mean7S.E.M, and were analyzed using two-way ANOVA followed by tukey's post hoc test. ***Po0.001
compared with the control vehicle treated group. #Po0.05 and ##Po0.01 compared with the ondansetron/tropisetron-treated group.
Fig. 6. Effect of PDE inhibitor on the antidepressant effect of 5-HT3 antagonists: Effect of subeffective dose of sildenaﬁl (5 mg/kg) on the effects of tropisetron (10 mg/kg) in
(A) FST (n¼8), (B) TST (n¼6–8), and (C) OFT (n¼8). Effect of subeffective dose of sildenaﬁl (5 mg/kg) on the effects of ondansetron (0.01 mg/kg) in (D) FST (n¼8), (E) TST
(n¼6–7), and (F) OFT (n¼8). Values are expressed as the mean7S.E.M, and were analyzed using two-way ANOVA followed by tukey's post hoc test. **Po0.01 and
***Po0.001 compared with the control vehicle treated group. #Po0.05 and ###Po0.001 compared with the ondansetron/tropisetron-treated group.
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Fig. 7. Hippocampal and cortical nitrite assay: Effect of tropisetron 1 mg/kg (n¼7–
8) and 10 mg/kg (n¼7–8), ondansetron 0.001 mg/kg (n¼7) and 0.01 mg/kg (n¼7)
administration on the level of nitrite in the hippocampus (A) and PFC (B) of ex-
perimental mice. Values are expressed as the mean7S.E.M., and were analyzed
using one-way ANOVA followed by tukey's post hoc test. *Po0.05 and **Po0.01
compared with the saline-treated (S) group (n¼7–8).
Fig. 8. Hippocampal and cortical nitrite assay: Effect of 7-NI (25 mg/kg, n¼7) ad-
ministration on the level of nitrite in the hippocampus (A) and PFC (B) of tropi-
setron (1 mg/kg, n¼7–8) and ondansetron (0.001 mg/kg, n¼7)-treated mice. Values
are expressed as the mean7S.E.M., and were analyzed using one-way ANOVA
followed by tukey's post hoc test. *Po0.05 and **Po0.01 compared with the ve-
hicle (Tween80/saline)-injected group (n¼7–8).
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Fig. 6E). In two-way ANOVA also we detected signiﬁcant or non-
signiﬁcant effect for ondansetron treatment (F (1, 28)¼9.836,
Po0.01) (F (1, 26)¼9.746, Po0.01), sildenaﬁl treatment (F (1,
28)¼13.68, Po0.001) (F (1, 26)¼1.847, P40.05), and their inter-
action (F (1, 28)¼18.73, Po0.001) (F (1, 26)¼6.895, Po0.05) in
FST and TST, respectively.
Sildenaﬁl, concurrent with saline or 5-HT3 antagonists, did not
affect the locomotor activity of mice when evaluated by two-way
analysis followed by tukey's multiple comparison tests (P40.05,
Fig. 6C and F).
3.5. Nitrite assay
One-way ANOVA revealed signiﬁcant effects of tropisetron and
ondansetron treatments on hippocampal nitrite levels (F (4, 33)¼
5.320, Po0.01, Fig. 7A). Tukey's post hoc showed that tropisetron
(10 mg/kg) and ondansetron (0.01 mg/kg) induced a signiﬁcant
decline in the hippocampal nitrite levels compared to saline-ad-
ministered animals (Po0.01 and Po0.05, respectively), while the
subeffective doses of these drugs, which were obtained from the
behavioral tests, did not decrease the nitrite level in hippocampus
(P40.05, Fig. 7). Obtained result was different in the PFC area;
one-way ANOVA analysis revealed that there was no signiﬁcant
difference in the cortical nitrite level between treated groups (F (4,
30)¼0.5340, P40.05, Fig. 7B). Also, tukey's post-test did not show
any signiﬁcant difference between tropisetron/ondansetron-trea-
ted groups and saline-administered mice (P40.05, Fig. 7B).
In the next part, the possible effect of 5-HT3 antagonists and
nNOS inhibitor co-administration on hippocampal (F (5, 37)¼
4.607, Po0.01, Fig. 8A) and cortical (F (5, 36)¼0.6467, P40.05,
Fig. 8B) nitrite level was evaluated. In hippocampal area, results
obtained from tukey's post hoc revealed that administration of
7-NI (25 mg/kg, subeffective dose) alone failed to alter the nitrite
content, however co-administration of subeffective 7-NI with the
subeffective doses of tropisetron (1 mg/kg) or ondansetron(0.001 mg/kg) caused a signiﬁcant decrease in hippocampal nitrite
levels compared with the animals receiving saline/Tween80
(Po0.01 and Po0.05 respectively, Fig. 8A). However, all treat-
ments as well as 5-HT3 antagonists and nNOS inhibitor co-ad-
ministration did not signiﬁcantly change the nitrite level of PFC in
animals (P40.05, Fig. 8B).4. Discussion
In this study, we have shown the antidepressant effect of tro-
pisetron and ondansetron in behavioral tests of despair; and
statistically, this effect is almost equal to the standard anti-
depressant ﬂuoxetine (Cryan et al., 2002). Our results revealed that
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fect of tropisetron and ondansetron. Also, administration of NO
precursor and PDE inhibitor mitigated the antidepressant effect of
these 5-HT3 antagonists. Considering these, we have determined
that the antidepressant effect of tropisetron and ondansetron is
partly mediated through NO-cGMP pathway. Furthermore, we
have found that these behavioral alterations are correlated with
decreased hippocampal (but not cortical) nitrite level. Therefore,
the hippocampal nitrergic system (especially nNOS) seems to be
partly involved in the antidepressant-like effects of tropisetron
and ondansetron. Although few earlier reports have challenged
the possible effective value of 5-HT3 antagonists in depression, to
our knowledge, no studies have been conducted to investigate
their exact mechanisms of action.
Antidepressant-like effect of ondansetron in the FST of male
mice had been investigated in past studies with which our results
are in accord (Ramamoorthy et al., 2008); however, our study for
the ﬁrst time reveals the dose-response effect of tropisetron in
models of depression in male mice. The antidepressant-like be-
havior of ondansetron and tropisetron in our experiments was not
related to the changes of locomotion and motoric behavior in the
OFT. Previous clinical investigations have reported that selective
antagonist of 5-HT3 receptors might be effective in treatment of
psychiatric disorders, including depression (Greenshaw and Sil-
verstone, 1997; Haus, 2000; Hewlett et al., 2003; Lecrubier et al.,
1993). Several experimental studies on animals provided evidence
of antidepressant effect of ondansetron in different animal models
of depression (Gupta et al., 2014; Martin et al., 1992; Ramamoorthy
et al., 2008); and few studies have investigated the effect of tro-
pisetron on behaviors related to depression in animal models, such
as the learned-helplessness paradigm (Bravo and Maswood, 2006;
Martin et al., 1992). In addition, recent studies have demonstrated
the antidepressant-like effect of novel serotonin type 3 antagonists
in FST without altering the baseline locomotor activity (Bhatt et al.,
2013; Kurhe et al., 2014; Mahesh et al., 2014).
Our results rules out the involvement of iNOS, since amino-
guanidine was not able to alter the effect of ondansetron and
tropisetron in behavioral tests. Our data are consistent with the
variety of evidence illustrating the role of NO in major depression
and mechanism of action of antidepressants (Joca and Guimarães,
2006). Numerous studies have indicated that NOS inhibition re-
sults in antidepressant-like behavioral effect in a variety of animal
tests of depression (Harkin et al., 1999). Interestingly, large body of
evidence from previous studies have focused on the involvement
of nNOS in the pathophysiology of depression (Heiberg et al.,
2002; Joca and Guimarães, 2006; Zhou et al., 2007). Since nNOS is
a more abundant isoenzyme in the CNS, especially hippocampus,
antidepressant effects of non-selective NOS inhibitors have been
mostly ascribed to nNOS (Guix et al., 2005; Steinert et al., 2010),
since it is known that over-expression of iNOS is mostly observed
during conditions such as inﬂammation and chronic stress (Harvey
et al., 2004; Olivenza et al., 2000); that might be the explanation of
our data regarding the experiments with aminoguanidine. On the
other hand, a decline in the NO level within the hippocampus was
shown to induce antidepressant-like effect, proposing the in-
volvement of endogenous hippocampal NO in neurobiology of
depression (Joca and Guimarães, 2006). Also, it has been shown
that endogenous NO exerts a negative control over the levels of
5-HT and dopamine and NOS inhibitors increase the 5-HT and
dopamine levels in the hippocampus (Wegener et al., 2000). Thus,
possibly the antidepressant effect of NOS inhibitors is mediated
through serotonergic and dopaminergic pathways. Nitric oxide has
been proposed to modulate synaptic transmission in several ways;
the most common is through activation of guanylate cyclase which
is responsible for an increase in cGMP (Garthwaite and Boulton,
1995). Animal studies have demonstrated that by regulating theeffect of cGMP (Denninger and Marletta, 1999), NO produces de-
pression-like state in an animal model (Spiacci Jr. et al., 2008).
Both the inhibition of soluble guanylate cyclase and weakening
NOS activity may decrease the level of cGMP and may produce
antidepressant-like behaviors (Ghasemi et al., 2008; Heiberg et al.,
2002). The cGMP is degraded into GMP by the action of phos-
phodiesterase enzyme (Eckeli et al., 2000). Sildenaﬁl, a 5-PDE in-
hibitor that causes an increase in level of cGMP in target tissues, is
able to prevent the antidepressant-like effect elicited by some
antidepressants (Dhir and Kulkarni, 2007; Ghasemi et al., 2008;
Zomkowski et al., 2010).
Detecting a lower level of nitrite in the hippocampus (but not
in the PFC) of ondansetron and tropisetron-treated mice plus the
ampliﬁcation of this nitrite reduction by 7-NI treatment is con-
sistent with our behavioral results. We have investigated the
hippocampal and cortical nitrite level because these region are of
the most susceptible structures in the brain to the negative effects
of stress due to presence of neural progenitor cells that conduct
neurogenesis, a pivotal phenomenon necessary for cognitive and
behavioral functions (Kempermann and Kronenberg, 2003; Sahay
and Hen, 2007; Warner-Schmidt and Duman, 2006). It has been
shown that nNOS expression density (under normal condition) is
signiﬁcantly higher in the hippocampus when compared with
other brain regions such as cortical area (Blackshaw et al., 2003;
Lourenço et al., 2014). Lourenço et al. studied the effect of L-glu-
tamate (a N-Methyl-D-aspartic acid receptor agonist which causes
intracellular calcium inﬂux and activates nNOS enzyme) on nNOS
activity in different brain structures including hippocampus and
cortex (Lourenço et al., 2014). They found that the hippocampus
has one of the highest NO content produced by local application of
L-glutamate as compared with the other brain regions such as
cortex. On the other hand, in our recent published study we have
shown that nNOS activity might be more prominent in the hip-
pocampus rather than cortical area (Amiri et al., 2015a).
5-HT3 receptors are ion channels and activation of these re-
ceptors results in considerable increase in intracellular calcium
level of hippocampus (Nayak et al., 1999). Calcium inﬂux triggers
multiple intracellular signaling cascades including nitrergic path-
way and activates NOS enzymes. Since 5-HT3 receptors are basi-
cally ion-channels, it is possible that blockade of these receptors
results in the reduction of calcium inﬂux and this effect inhibits
the nNOS enzyme, which is calcium dependent. Reduction of the
nNOS activity causes antidepressant effects through decreasing NO
production (Joca and Guimarães, 2006; Zhou et al., 2007). The
functional connection between the serotonergic and NO pathways
has been also demonstrated previously, when it was reported that
inhibiting the NOS enzyme could be used as a strategy to
strengthen the clinical effect of serotonergic antidepressants
(Harkin et al., 1999). In addition, contribution of NO to some per-
ipheral (Sévoz-Couche et al., 2002) and central (Gholipour et al.,
2010) effects of 5-HT3 receptors have been understood. As ex-
amples, an observation by Javadi-Paydar et al. with application of
the scopolamine-induced memory impairment in mice, suggested
the involvement of nitric oxide in the enhancing effect of 5-HT3
antagonist on memory (Javadi-Paydar et al., 2012). Also, in a recent
study, QCM-4, a novel 5-HT3 antagonist, attenuated the brain ni-
trite level elevation due to chronic mild stress in mice (Kurhe et al.,
2014). In our recent published study, we have also shown that
tropisetron induces its anxiolytic effect in social isolation stress
paradigm through inhibition of hippocampal NOS (especially
iNOS) activity (Amiri et al., 2015b). However, therewith we found
the prominent role of iNOS, but not nNOS enzyme; because,
chronic stress induces neuroinﬂammation in brain regions such as
cortex and hippocampus and causes an increase in expression of
iNOS enzyme which is not expressed in normal conditions such as
that in the current study.
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In conclusion, our results demonstrate that tropisetron and
ondansetron, the 5-HT3 receptor antagonists exert antidepressant-
like effect in mouse, when administered through the i.p route. The
data from our current study also suggest that the antidepressant-
like effect of tropisetron and ondansetron is mediated by inhibi-
tion of NO-cGMP pathway. But, undeniably, it remains to be ex-
plored whether the contribution of nitrergic system in acute an-
tidepressant effect of these 5-HT3 antagonists is of value in clinical
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